Beta-blockers have long been considered a foundational therapy following myocardial infarction, yet emerging data are challenging their routine use in all patients. This course discusses recent evidence on outcomes associated with beta-blocker therapy after MI, particularly in patients without reduced ejection fraction, and explores the ongoing debate over the benefits, risks, and duration of therapy. You will gain practical insight to support evidence-based decision-making and individualized pharmacotherapy recommendations in post-MI care.
HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpact
GUESTS
Anna Crider, PharmD, BCCP
Clinical Pharmacy Specialist,
Emory University Hospital
Taylor Merritt, PharmD
PGY2 Internal Medicine Pharmacy Resident, Chief Pharmacy Resident,
Emory University Hospital
GET CE FOR LISTENING!
Stay Compliant. Grow Clinically. Practice with Confidence.
Pharmacist CE Subscription: All your CE in one convenient subscription.
All episodes, CE, and Practice Resources for the GameChangers Clinical Update is included with your Pharmacist CE Subscription. But wait…there’s even more!
The Pharmacist CE Subscription includes:
- Compliance and licensure CE
- GameChangers Clinical Updates
- Practical continuing education across patient care topics
*The subscription does not include microcredentials or certificates, which are available separately for pharmacists seeking specialized service training.
Purchase Now!
PRACTICE RESOURCE
Receive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the Pharmacist CE Subscription.
CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:
CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Summarize contemporary evidence regarding beta-blocker therapy after myocardial infarction.
2. Describe clinical considerations that may influence the decision to initiate, continue, or deprescribe beta-blocker therapy following myocardial infarction.
Rachel Maynard, Anna Crider, and Taylor Merritt have no relevant financial relationships to disclose.
0.075 CEU/0.75 Hr
UAN: 0107-0000-26-242-H01-P
Initial release date: 6/29/2026
Expiration date: 6/29/2027
Additional CPE details can be found here.
Follow CEimpact on Social Media:
LinkedIn
Instagram
